Irsogladine maleate inhibits angiogenesis in wild-type and plasminogen activator-deficient mice

Journal of Surgical Research

Volumn 77, Issue 2, 1998, Pages 126-131

  Ren, Christine J ^a   Ueda, Fusao ^b   Roses, Daniel F ^a   Harris, Matthew N ^a   Mignatti, Paolo ^a   Rifkin, Daniel B ^a   Shapiro, Richard L ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Angiogenesis; Irsogladine; Knockout mice; Plasminogen activators

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; IRSOGLADINE MALEATE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DRUG EFFECT; KNOCKOUT MOUSE; MEDICAL PHOTOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SLIT LAMP; VASCULARIZATION;

EID: 0032124519     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1998.5381     Document Type: Article

References (31)

1. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue. Cancer Res. 46:1986;467.
2. Schweizerer L., Neufeld G., Friedman J., Abraham A., Fidder J. C., Gospodarowicz D. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature. 325:1987;257.
3. Moscatelli D., Presta M., Rifkin D. B. Purification of a factor from human placenta that stimulates capillary endothelial cells protease production, DNA synthesis and migration. Proc. Natl. Acad. Sci. USA. 83:1986;2091.
4. Mignatti P., Rifkin D. B. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73:1993;161.
5. De Bruin P. A. F., Griffioen G., Verspaget H. W., Verheijen J. H., Dooijewaard G., van den Ingh H. F., Lamers C. Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res. 48:1988;4520.
6. Xing R. H., Rabbani S. A. Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis. Int. J. Cancer. 67:1996;423.
7. Ellis L. M., Fidler I. J. Angiogenesis and metastasis. Eur. J. Cancer. 14:1996;2451.
8. Chen C., Parangi S., Tolentino M. J., Folkman J. A strategy to discover circulating angiogenesis inhibitors generated by human tumors. Cancer Res. 55:1995;4230.
9. Weidner N., Semple J. P., Welch W. R., Folkman J. Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma. N. Engl. J. Med. 324:1991;1.
10. Folkman J. What is the evidence that tumors are angiogenesis dependent. J. Natl. Cancer Inst. 82:1990;4.
11. Pyke C., Kristensen P., Ralfkiaer E., Grøndahl-Hansen J., Eriksen J., Blasi F., Danø K. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am. J. Pathol. 138:1991;1059.
12. Sim P., Stephens R. W., Fayle D. R., Doe W. F. Urokinase-type plasminogen activator in colorectal carcinomas and adenomatous polyps: Quantitative expression of active and proenzyme. Int. J. Cancer. 42:1988;483.
13. de Vries T. J., Quax P. H., Denijn M., Verrijp K. N., Verheijen J. H., Verspaget H. W., Weidle U. H., Ruiter D. J., van Muijen G. N. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am. J. Pathol. 144:1994;70.
14. Verspaget H. W., Sier C. F. M., Ganesh S., Griffioen G., Lamers C. B. Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. Eur. J. Cancer. 31A:1995;1105.
15. Janicke F., Schmitt M., Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin. Thromb. Hemostasis. 17:1991;303.
16. Ossowski L., Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell. 35:1983;611.
17. Ossowski L. Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo. Cell. 52:1988;321.
18. Ossowski L., Russo-Payne H., Wilson E. L. Inhibition of urokinase-type plasminogen activator by antibodies: The effect on dissemination of a human tumor in the nude mouse. Cancer Res. 51:1991;274.
19. O'Reilly M. S., Holmgren L., Shing Y., Chen C., Rosenthal R. A., Moses M., Lane W. S., Cao Y., Sage E. H., Folkman J. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:1994;315.
20. O'Reilly M. S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W. S., Flynn E., Birkhead J. R., Olsen B. R., Folkman J. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:1997;277.
21. Ono M., Kawahara N., Goto D., Wakabayashi Y., Ushiro S., Toshida S., Izumi H., Kuwano M., Sato Y. Inhibition of tumor growth and neovascularization by an anti-gastric ulcer agent, Irsogladine. Cancer Res. 56:1996;1512.
22. Sato Y., Morimoto A., Kiue A., Okamura K., Hamanaka R., Kohno K., Kuwano M., Sakata T. Irsogladine is a potent inhibitor of angiogenesis. FEBS Lett. 322:1993;155.
23. Kenyon B. M., Voest E. E., Chen C., Flynn E., Folkman J., D'Amato R. J. A model of angiogenesis in the mouse cornea. Invest. Ophthal. Visual Sci. 37:1996;1625.
24. Folkman J. Tumor angiogenesis. The Molecular Basis of Cancer. 1995;Saunders, Philadelphia. p. 206-232.
25. Sato Y., Rifkin D. B. Autocrine activities of basic fibroblast growth factor: Regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J. Cell Biol. 107:1988;1199.
26. Mignatti P., Tsuboi R., Robbins E., Rifkin D. B. In vitro angiogenesis on the human amniotic membrane: Requirement for basic fibroblast growth factor-induced proteinases. J. Cell Biol. 108:1989;671.
27. Carmeliet P., Schoonjans L., Kieckens L., Ream B., Began J., Bronson R., De Vos R., van den Oord J. J., Colen D., Mulligan R. C. Physiological consequences of loss of plasminogen activator gene function in mice. Nature. 368:1994;419.
28. Shapiro R. L., Duquette J. G., Nunes I., Roses D. F., Harris M. N., Wilson E. L., Rifkin D. B. Urokinase-type plasminogen activator-deficient mice are predisposed to staphylococcal botryomycosis, pleuritis, and effacement of lymphoid follicles. Am. J. Pathol. 150:1997;359.
29. Gyetko M. R., Chen G. H., McDonald R. A., Goodman R., Huffnagle G. B., Wilkinson C. C., Fuller J. A., Toews G. B. Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. J. Clin. Invest. 97:1996;1818.
30. Danø K., Andreasen P. A., Grøndahl-Hansen J., Kristensen P., Nielson L. S., Skirver L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res. 44:1985;139.
31. Shapiro R. L., Duquette J. G., Roses D. F., Nunes I., Harris M. N., Kamino H., Wilson E. L., Rifkin D. B. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res. 56:1996;3597.